Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Age-Adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL)

NCT01662050 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT01662050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01662050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Age-Adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL)
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2012
Completion date
September 11, 2017
Enrollment
57 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma